title: Status of the coagulation and fibrinolytic systems in ovarian hyperstimulation syndrome.
abstract: OBJECTIVE
  To elucidate characteristic changes of plasma hemostatic markers in ovarian hyperstimulation syndrome (OHSS) cycles.
  
  
  METHODS
  Prospective study.
  
  
  METHODS
  The IVF-ET program of the Department of Obstetrics and Gynecology, The University of Akita, School of Medicine.
  
  
  METHODS
  Forty cycles of 40 IVF patients, including 12 cycles in which a severe form of OHSS occurred.
  
  
  METHODS
  Blood samples were taken during IVF treatment to determine the levels of blood markers that reflect activation of the coagulation and fibrinolytic systems.
  
  
  METHODS
  Thrombin-antithrombin III complexes, plasmin-alpha 2 antiplasmin complexes, and other hemostatic markers related to the coagulation and fibrinolytic system activation.
  
  
  RESULTS
  In the OHSS cycles, the levels of thrombin-antithrombin III and plasmin-alpha 2 antiplasmin complexes in the plasma began to rise within a few days after hCG administration and demonstrated significantly higher levels during the midluteal phase. In OHSS cycles with pregnancy, elevation of these markers continued for > or = 3 weeks after the onset of disease. There were some characteristic changes in OHSS cycles in other hemostatic markers, such as a decrease in the levels of antithrombin III and prekallikrein and shortened activated partial thromboplastin time.
  
  
  CONCLUSIONS
  These data demonstrate the status of the coagulation and fibrinolytic systems in OHSS cycles and provide insight into the mechanism of activation in the hemostatic system.
authors: Department of Obstetrics and Gynecology, Akita University School of Medicine, Japan.
authors: H
authors: H
authors: Kodama
authors: J
authors: J
authors: Fukuda
authors: H
authors: H
authors: Karube
authors: T
authors: T
authors: Matsui
authors: Y
authors: Y
authors: Shimizu
authors: T
authors: T
authors: Tanaka
mesh_terms: D000328:Adult; D000933:Antifibrinolytic Agents; D000990:Antithrombin III / Q000032:analysis; D001777:Blood Coagulation / Q000502:physiology*; D006063:Chorionic Gonadotropin / Q000494:pharmacology; D005260:Female; D005307:Fertilization in Vitro; D005341:Fibrinolysin / Q000032:analysis; D005342:Fibrinolysis / Q000502:physiology*; D006487:Hemostasis / Q000502:physiology; D006801:Humans; D016471:Ovarian Hyperstimulation Syndrome / Q000097:blood* / Q000503:physiopathology; D010314:Partial Thromboplastin Time; D010447:Peptide Hydrolases / Q000032:analysis; D011247:Pregnancy; D011288:Prekallikrein / Q000032:analysis; D011446:Prospective Studies; D013997:Time Factors; D000979:alpha-2-Antiplasmin / Q000032:analysis
chemical_list: D000933:Antifibrinolytic Agents; D006063:Chorionic Gonadotropin; D000979:alpha-2-Antiplasmin; C046193:antithrombin III-protease complex; C037742:plasmin-plasmin inhibitor complex; D000990:Antithrombin III; D011288:Prekallikrein; D010447:Peptide Hydrolases; D005341:Fibrinolysin